By a News Reporter-Staff News Editor at Biotech Week -- New research on Immunology is the subject of a report. According to news reporting originating from San Francisco, California, by NewsRx correspondents, research stated, "Therapeutic monoclonal antibodies (mAb) are often produced in Chinese hamster ovary (CHO) cells. Three commonly used CHO host cells for generating stable cell lines to produce therapeutic proteins are dihydrofolate reductase (DHFR) positive CHOK1, DHFR-deficient DG44, and DUXB11-based DHFR deficient CHO."
Our news editors obtained a quote from the research from Genentech, Inc., "Current Genentech commercial full-length antibody products have all been produced in the DUXB11-derived DHFR-deficient CHO host. However, it has been challenging to develop stable cell lines producing an appreciable amount of antibody proteins in the DUXB11-derived DHFR-deficient CHO host for some antibody molecules and the CHOK1 host has been explored as an alternative approach. In this work, stable cell lines were developed for three antibody molecules in both DUXB11-based and CHOK1 hosts. Results have shown that the best CHOK1 clones produce about 1 g/l for an antibody mAb1 and about 4 g/l for an antibody mAb2 in 14-day fed batch cultures in shake flasks. In contrast, the DUXB11-based host produced approximate to 0.1 g/l for both antibodies in the same 14-day fed batch shake flask production experiments. For an antibody mAb3, both CHOK1 and DUXB11 host cells can generate stable cell lines with the best clone in each host producing approximate to 2.5 g/l."
According to the news editors, the research concluded: "Additionally, studies have shown that the CHOK1 host cell has a larger endoplasmic reticulum and higher mitochondrial mass."
For more information on this research see: Chinese hamster ovary K1 host cell enables stable cell line development for antibody molecules which are difficult to express in DUXB11-derived dihydrofolate reductase deficient host cell. Biotechnology Progress, 2013;29(4):980-985. Biotechnology Progress can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (American Chemical Society - www.acs.org; Biotechnology Progress - www.pubs.acs.org/journal/bipret)
The news editors report that additional information may be obtained by contacting Z.L. Hu, Genentech Inc, Dept. of Early Stage Cell Culture, San Francisco, CA 94080, United States. Additional authors for this research include D.L. Guo, S.S.M. Yip, D.J. Zhan, S. Misaghi, J.C. Joly, B.R. Snedecor and A.Y. Shen (see also Immunology).
Keywords for this news article include: Antibodies, Reductase, California, Immunology, San Francisco, United States, Blood Proteins, Immunoglobulins, Enzymes and Coenzymes, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC